Pharmaceutical Company
Appears in 1 story
Developer of NHWD-870; reported Phase II results at ESMO 2026
NUT carcinoma is a rare, aggressive cancer with no targeted therapy and a median survival measured in months. At the European Society for Medical Oncology's (ESMO) 2026 annual meeting on October 24, Zhejiang Wenda Pharma reported its oral drug NHWD-870 produced a 30% response rate in a 40-patient Phase II trial. Among 20 patients whose tumors began in the chest, the response rate was 45%.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
